Published: 16 March 2022
Author(s): F. Calabretta, P.S. Preti, M. Russo, C. Klersy, A. Di Sabatino
Issue: July 2022
Section: Letter to the Editor

Many COVID-19 patients develop a coagulopathy characterized by thrombocytopenia, minor prolongation of bleeding times and elevated serum d-dimer and fibrinogen levels, similar to consumption coagulopathy [1], together with severe endothelial injury, and alveolar capillary microthrombi [2]. Moreover, several studies reported an increased risk of venous thromboembolism (VTE), disseminated intravascular coagulation (DIC), as well as large-vessel thrombosis. In particular, the incidence of VTE in COVID-19 patients was 8 to 69% [3], which is significantly higher than in critically ill patients with H1N1 influenza and sepsis.

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

randomness